Research and Development in Biotechnology
NAICS 541711 · Federal Contracts & Awards
$17,850,721,064.74 is the USAspending.gov obligation sum for Research And Development In Biotechnology in fiscal year 2024. Under NAICS 541711, that yearlyTrend cell is 97.8% of the industry's $18,258,755,045.17 extract-wide total — almost the entire published series sits in this year. The pair is biotechnology R&D plus FY2024, not a trial census and not cash already paid. The extract publishes 473 541711 award records industry-wide, a compact file that is not a FY2024-only grant list.
Key figures
- USAspending records $17,850,721,064.74 in Research And Development In Biotechnology FY2024 obligations (NAICS 541711).
- FY2024 is 97.8% of the industry's $18,258,755,045.17 extract-wide total.
- NAICS 541714 is a different biotechnology R&D code, not this cell.
- 473 is an industry-extract award-record count, not a FY2024 grant census.
541711 dollars tagged to FY2024
NAICS 541711 and fiscal year 2024 form one pair. $17,850,721,064.74 is the obligation sum USAspending.gov attaches to that pair. It is not Research And Development In Biotechnology (Except Nanobiotechnology) coded 541714, not the $18,258,755,045.17 all-year 541711 book as a second addend, and not an outlay. 541714 has its own FY2024 cell on this slice. The packet does not name labs or principal investigators.
A near-complete year-share can look like a closed R&D program. Other years still exist as other rows even when 97.8% is high. Ranking campuses from this total would invent a table. Correlation with trial headlines is not causation.
FY2024 versus 541711's extract-wide total
97.8% of $18,258,755,045.17 sits on the FY2024 yearlyTrend row. The Research And Development In Biotechnology hub (/industries/541711/) drops the year filter. FY2024 federal spending (/fiscal-years/2024/) drops the 541711 filter. Neither parent equals $17,850,721,064.74.
Do not add 541714's FY2024 cell into this 541711 total. Different NAICS strings are different joins even when both mention biotechnology. Cite $17,850,721,064.74 as obligations, not as grants already drawn by a named campus.
Full analysis: Research And Development In Biotechnology federal obligations in FY2024 →
Questions
- How much did biotechnology R&D obligate in FY2024?
- USAspending.gov records $17,850,721,064.74 in Research And Development In Biotechnology obligations for FY2024 under NAICS 541711. That yearlyTrend total is not an outlay and not the industry's $18,258,755,045.17 extract-wide sum. Keep Research And Development In Biotechnology and FY2024 on the same citation as $17,850,721,064.74.
- Is this the same as NAICS 541714 biotechnology R&D?
- No. This join is 541711. 541714 is Research And Development In Biotechnology (Except Nanobiotechnology), a different code with its own FY2024 cell. FY2024 is 97.8% of 541711's $18,258,755,045.17 extract-wide total. 473 is the industry extract award-record count, not a FY2024 headcount.
- Are 473 awards the FY2024 biotech grant count?
- No. 473 is the 541711 extract award-record count, not a FY2024-only tally. The packet does not name labs. Obligations of $17,850,721,064.74 are not outlays. The pair is NAICS 541711 plus FY2024. The pair is NAICS 541711 plus FY2024.
- Does this page report trial funding already paid?
- No. $17,850,721,064.74 is an obligation aggregate. Outlays, campus shares, and investigator names are unpublished. FEC donations are a different dataset and do not fund this total. USAspending.gov remains the source for NAICS 541711 in FY2024.
USAspending.gov NAICS yearlyTrend by fiscal year. Obligations are not outlays. FY figures can be incomplete for the current year.
Industry ties
- Research And Development In Biotechnology federal obligations in FY2024
- Research and Development in Biotechnology in Colorado 7th District (CO-07)
- Research And Development In Biotechnology in Maryland 6th District (MD-06)
- Biotechnology R&D in New York 17th District (NY-17)
- Research And Development In Biotechnology federal obligations in FY2025
Companies in the Research and Development in Biotechnology industry (NAICS code 541711) have received $18.26B in federal contracts, grants, and other awards since FY2024, across 473 individual awards tracked through FY2026. The largest funding agency is Department of Energy ($10.30B). Spending is concentrated in Colorado, Maryland, New York and 30 other states. All figures below come from USAspending.gov award records.
Total Obligations
$18.26B
Total Awards
473
States
33
Last Updated
Mar 26, 2026
Yearly Spending Trend
$17.85B24
$371.2M25
$36.9M26
Top 50 Awards in Research and Development in Biotechnology
Largest individual obligations in NAICS 541711.
| Award | Recipient | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|---|
CONT_AWD_DEAC3608GO28308_8900_-NONE-_-NONE- MODIFICATION NUMBER 1490 PROVIDES TOTAL FUNDING IN THE AMOUNT OF $1,667,500.00. THIS INCLUDES APPROPRIATED FUNDING IN THE AMOUNT OF $1,667,500.00 AND IS REPORTED IN FPDS-NG, THE R… | ALLIANCE FOR ENERGY INNOVATION, LLC Colorado | Department of Energy Department of Energy | — | LAKEWOOD, CO-07 | 2024 | $10,301,736,516 |
CONT_AWD_HHSO100201600030C_7505_-NONE-_-NONE- EO14042 EMERGENT AV7909 ANTHRAX VACCINE | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. Maryland | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | GAITHERSBURG, MD-06 | 2024 | $1,385,742,139 |
CONT_IDV_HHSO100201700018C_7505 EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE WORK AND DEOBLIGATE FUNDS. | JANSSEN PHARMACEUTICALS, INC. New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $919,512,953 |
CONT_AWD_HHSO100201700016C_7505_-NONE-_-NONE- NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.1., ARTICLE C.1., ARTICLE F.4, , ARTICLE G.4. AND THE STATEMENT OF WORK. | REGENERON PHARMACEUTICALS INC New York | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | TARRYTOWN, NY-17 | 2024 | $693,056,927 |
CONT_AWD_HHSO100201700020C_7505_-NONE-_-NONE- NO COST MODIFICATION TO REVISE THE JOINT OVERSIGHT COMMITTEE MEMBERS AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 0001 TO SEPT 25, 2027. | REGENERON PHARMACEUTICALS INC New York | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | TARRYTOWN, NY-17 | 2024 | $611,318,728 |
CONT_IDV_HSHQDC15C00064_7001 MODIFICATION TO REALIGN FUNDING ON CLINS 8202 AND 8302 | BATTELLE NATIONAL BIODEFENSE INSTITUTE, LLC Maryland | Department of Homeland Security Office of Procurement Operations | — | — | 2024 | $329,628,151 |
CONT_AWD_HHSO100201700012C_7505_-NONE-_-NONE- MERCK - EBOLA ZAIRE VACCINE EXERCISE AND FUND OPTION 6 IN ORDER TO CONTINUE TO MEET THE REQUIREMENT OF MAINTAINING 1.13 MILLION DOSES OF ERVEBO. | MERCK SHARP & DOHME LLC New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | WHITEHOUSE STATION, NJ-07 | 2024 | $236,307,634 |
CONT_IDV_HHSO100201300011C_7505 THE PURPOSE OF THIS AGREEMENT MODIFICATION IS ADD LAURA SADDISON AS A NON-VOTING JOC MEMBER AT NO ADDITIONAL COST TO THE GOVERNMENT. | GLAXOSMITHKLINE, LLC North Carolina | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $215,851,503 |
CONT_AWD_HHSO100201600009C_7505_-NONE-_-NONE- THE PURPOSE OF THIS NO COST MODIFICATION IS TO ADMINISTRATIVELY CORRECT THE CONTRACT CLINS PERIOD OF PERFORMANCE IN THE PRISM CONTRACT WRITING SYSTEM IN ORDER TO ALIGN IT FOR INVO… | CERUS CORPORATION California | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | CONCORD, CA-10 | 2024 | $185,466,764 |
CONT_AWD_HHSO100201600038C_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO UPDATE COST SHARE AMOUNT AND ADD SUPPLEMENTAL FUNDING TO CLIN 0002. | HOFFMANN-LA ROCHE INC. New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | LITTLE FALLS, NJ-11 | 2024 | $157,343,419 |
CONT_AWD_HHSN272201600013C_7529_-NONE-_-NONE- MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) | AMERICAN TYPE CULTURE COLLECTION Virginia | Department of Health and Human Services National Institutes of Health | — | MANASSAS, VA-10 | 2024 | $140,973,859 |
CONT_AWD_HHSO100201000026C_7505_-NONE-_-NONE- ELUSYS 0026C MOD#1 9 DE-OB CANCELLING FUNDS | ELUSYS THERAPEUTICS INC New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | PINE BROOK, NJ-11 | 2024 | $138,258,202 |
CONT_AWD_HHSO100201700013C_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE STATEMENT OF WORK TO PROVIDE ADDITIONAL INFORMATION | JANSSEN VACCINES & PREVENTION B.V. | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $132,282,550 |
CONT_AWD_W911QY13C0056_9700_-NONE-_-NONE- EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | DYNPORT VACCINE COMPANY LLC Maryland | Department of Defense Department of the Army | — | FREDERICK, MD-06 | 2024 | $117,632,941 |
CONT_AWD_HHSO100201500035C_7505_-NONE-_-NONE- THERMAL BURN DEBRIDEMENT LICENSURE, APPROVAL AND CLEARANCE OF PRODUCT THROUGH THE FDA | MEDIWOUND LTD | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $117,518,418 |
CONT_AWD_HHSO100201600002C_7505_-NONE-_-NONE- ADVANCED DEVELOPMENT OF CEFTOBIPROLE | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $110,632,461 |
CONT_AWD_HHSO100201600026C_7505_-NONE-_-NONE- ADD THE DEFINITION OF "DISCONTINUED PROGRAM" TO SECTION 1.B; ADD LANGUAGE TO THE "ORAVANCE PROGRAM" DEFINITION THAT STATES THE REMOVAL OF FURTHER PROGRESSION OF S-743229 FROM THE… | MEDICINES COMPANY, THE New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | PARSIPPANY, NJ-11 | 2024 | $98,144,230 |
CONT_AWD_HHSN272201400008C_7529_-NONE-_-NONE- NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI New York | Department of Health and Human Services National Institutes of Health | — | NEW YORK, NY-13 | 2024 | $79,763,886 |
CONT_IDV_HHSO100201500010C_7505 THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE $2,863,538.00 FROM CONTRACT HHSO100201500010C. POP ENDED ON 5/21/2024. | GLAXOSMITHKLINE, LLC North Carolina | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $78,310,394 |
CONT_AWD_HHSO100201500027C_7505_-NONE-_-NONE- EO14042 - CELL BASED SKIN SUBS FOR DEFINITIVE CARE OF BURN INJURIES | STRATATECH CORPORATION Wisconsin | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | MADISON, WI-02 | 2024 | $74,851,753 |
CONT_AWD_75A50120F33002_7505_HHSO100201400002I_7505 CRO ASSISTANCE FOR THE ACTIV-1 MASTER PROTOCOL | TECHNICAL RESOURCES INTERNATIONAL, INC. Maryland | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | BETHESDA, MD-08 | 2024 | $74,513,740 |
CONT_AWD_HHSO100201600029C_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDING IN THE AMOUNT OF $6,336.92 IN CANCELLING FUNDS FROM CLIN 0001. | MODERNATX, INC. Massachusetts | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | CAMBRIDGE, MA-07 | 2024 | $72,965,186 |
CONT_AWD_HHSO100201500029C_7505_-NONE-_-NONE- THE PURPOSE OF MODIFICATION P00013 IS TO DE-OBLIGATE CANCELING FUNDS | PFIZER INC New York | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $69,739,002 |
CONT_AWD_HHSO100201600031C_7505_-NONE-_-NONE- MODIFICATION P00007 THIS MODIFICATION IS BEING ISSUED TO DE-OBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $235,502.00. | MERCK SHARP & DOHME LLC New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | AMES, IA-04 | 2025 | $65,103,309 |
CONT_IDV_HHSO100201100034C_7505 THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO DE-OBLIGATE CANCELING FUNDS FROM REQUISITION OS212728 OF $282,172.97, UPDATE SECTION F.2. DELIVERABLES, AND G.5. INVOICES/FINANCIN… | ELUSYS THERAPEUTICS INC New Jersey | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $62,146,948 |
CONT_IDV_HHSO100201700014C_7505 THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES CANCELING FUNDS FROM REQUISITION OS250781 IN THE AMOUNT OF -$3,174,640.95 FROM CLIN0005, UPDATES SECTIONS G.1 CONTRACTING O… | SUMMIT (OXFORD) LIMITED | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2025 | $59,203,413 |
CONT_AWD_HHSN275201700002C_7529_-NONE-_-NONE- DATA COORDINATING CENTER FOR THE BEST PHARMACEUTICALS FOR CHILDREN ACT | THE EMMES COMPANY, LLC Maryland | Department of Health and Human Services National Institutes of Health | — | ROCKVILLE, MD-08 | 2024 | $55,340,350 |
CONT_AWD_HHSO100201500008C_7505_-NONE-_-NONE- NO COST MODIFICATION TO CLOSEOUT THE CONTRACT IN ITS ENTIRETY. | JANSSEN VACCINES & PREVENTION B.V. | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $48,930,332 |
CONT_AWD_HHSN272201600029C_7529_-NONE-_-NONE- THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEV… | VENATORX PHARMACEUTICALS INC Pennsylvania | Department of Health and Human Services National Institutes of Health | — | MALVERN, PA-06 | 2024 | $48,773,739 |
CONT_AWD_HHSO100201500004C_7505_-NONE-_-NONE- ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. Maryland | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | GAITHERSBURG, MD-06 | 2024 | $43,794,113 |
CONT_AWD_HHSO100201600017C_7505_-NONE-_-NONE- DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES) | DNAE GROUP HOLDINGS LIMITED | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $43,409,723 |
CONT_AWD_HHSN273200800005C_7529_-NONE-_-NONE- NTP/NIEHS ARCHIVES AND REPOSITORY MANAGEMENT AND SUPPORT | EXPERIMENTAL PATHOLOGY LABORATORIES, INC. Virginia | Department of Health and Human Services National Institutes of Health | — | DURHAM, NC-04 | 2025 | $41,581,952 |
CONT_AWD_HHSO100201500028C_7505_-NONE-_-NONE- AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES | AVITA MEDICAL AMERICAS, LLC California | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | NORTHRIDGE, CA-32 | 2024 | $40,800,433 |
CONT_AWD_HHSN272200800044C_7529_-NONE-_-NONE- TO DE-OBLIGATE REMAINING FUNDS AND ADMINISTRATIVELY CLOSE THE CONTRACT. | FISHER BIOSERVICES INC Maryland | Department of Health and Human Services National Institutes of Health | — | ROCKVILLE, MD-08 | 2025 | $40,769,875 |
CONT_AWD_HHSO100201500021C_7505_-NONE-_-NONE- THE PURPOSE OF THIS BILATERAL ADMINISTRATIVE MODIFICATION IS TO CHANGE THE KEY PERSONNEL AND ADD AN ALTERNATE COR. 1. CHANGE ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR… | POLYNOVO BIOMATERIALS PTY LTD | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $38,882,504 |
CONT_AWD_HHSN272201400004C_7529_-NONE-_-NONE- EO14042: NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | EMORY UNIVERSITY Georgia | Department of Health and Human Services National Institutes of Health | — | ATLANTA, GA-05 | 2024 | $38,463,167 |
CONT_AWD_HHSN272201400005C_7529_-NONE-_-NONE- NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS). | UNIVERSITY OF ROCHESTER New York | Department of Health and Human Services National Institutes of Health | — | ROCHESTER, NY-25 | 2024 | $37,729,389 |
CONT_AWD_W81XWH11C0516_9700_-NONE-_-NONE- CLINICAL TRIAL SUPPORT SERVICES FOR WRAIR | ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC. Ohio | Department of Defense Department of the Army | — | SILVER SPRING, MD-08 | 2024 | $35,222,551 |
CONT_IDV_HHSO100201500013C_7505 DE-OBLIGATE FISCAL YEAR 2024 CANCELING FUNDS. | REGENERON PHARMACEUTICALS INC New York | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2024 | $33,135,560 |
CONT_AWD_HHSO100201700001C_7505_-NONE-_-NONE- PUT A STOP TO TASKS THAT ARE NO LONGER NEEDED | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. Maryland | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | GAITHERSBURG, MD-06 | 2024 | $32,952,759 |
CONT_AWD_HHSO100201600008C_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO CLOSE THIS CONTRACT IN LINE WITH FAR 4.804 | ALTIMMUNE, INC. Maryland | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | GAITHERSBURG, MD-06 | 2024 | $29,928,823 |
CONT_AWD_HHSN272201200022C_7529_-NONE-_-NONE- AIDS REAGENT PROGRAM (ARP) | FISHER BIOSERVICES INC Maryland | Department of Health and Human Services National Institutes of Health | — | ROCKVILLE, MD-08 | 2024 | $29,421,403 |
CONT_AWD_HHSN272201600028C_7529_-NONE-_-NONE- THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC. | ABVIRO LLC Maryland | Department of Health and Human Services National Institutes of Health | — | BETHESDA, MD-08 | 2024 | $29,175,011 |
CONT_AWD_HHSN272201400007C_7529_-NONE-_-NONE- TO DE-OBLIGATE REMAINING FUNDS AND ADMINISTRATIVELY CLOSE THE CONTRACT. | THE JOHNS HOPKINS UNIVERSITY Maryland | Department of Health and Human Services National Institutes of Health | — | BALTIMORE, MD-07 | 2024 | $27,856,129 |
CONT_AWD_HHSN271201100013C_7529_-NONE-_-NONE- MEDICINAL CHEMISTRY FOR NEUROTHERAPEUTICS PROGRAM | CURIA GLOBAL INC New York | Department of Health and Human Services National Institutes of Health | — | ALBANY, NY-20 | 2024 | $27,277,165 |
CONT_AWD_HHSN272201200004C_7529_-NONE-_-NONE- NIAID DAIT CLINICAL SITE MONITORING CENTER | PPD DEVELOPMENT LP North Carolina | Department of Health and Human Services National Institutes of Health | — | WILMINGTON, NC-07 | 2025 | $27,247,204 |
CONT_AWD_W81XWH20F0253_9700_W81XWH16D0009_9700 CONTRACTOR-ACQUIRED PROPERTY (CAP) AND GOVERNMENT FURNISHED EQUIPMENT | INBIOS INTERNATIONAL INC Washington | Department of Defense Defense Health Agency | — | SEATTLE, WA-07 | 2024 | $25,655,995 |
CONT_IDV_HHSO100201700030C_7505 DE-OBLIGATE REMAINING FUNDS AND CLOSEOUT THE AWARD. | SRI INTERNATIONAL California | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | — | 2026 | $25,540,532 |
CONT_AWD_HHSN272201400028C_7529_-NONE-_-NONE- BIOINFORMATIC RESOURCE CENTERS FOR INFECTIOUS DISEASES | PERATON INC. Virginia | Department of Health and Human Services National Institutes of Health | — | MCLEAN, VA-11 | 2024 | $23,385,247 |
CONT_AWD_W81XWH15C0048_9700_-NONE-_-NONE- FREEZE DRIED PLASMA CLINICAL TRIAL FOR BLA RESUBMISSION. | WESTAT, INC. Maryland | Department of Defense Defense Health Agency | — | ROCKVILLE, MD-08 | 2024 | $22,748,424 |
Top 50 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Top Funding Agencies
View All→12345678910
Department of Energy$10.30B
Department of Health and Human Services$7.25B
Department of Homeland Security$379.0M
Department of Defense$321.1M
Department of Veterans Affairs$6.0M
Department of the Interior$1.6M
Department of Transportation$414K
Environmental Protection Agency$21K
Department of Agriculture$10K
General Services Administration$0
Top Recipients
View All→12345678910
ALLIANCE FOR ENERGY INNOVATION, LLC$10.30B
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.$1.46B
REGENERON PHARMACEUTICALS INC$1.35B
JANSSEN PHARMACEUTICALS, INC.$919.5M
BATTELLE NATIONAL BIODEFENSE INSTITUTE, LLC$374.9M
MERCK SHARP & DOHME LLC$301.4M
GLAXOSMITHKLINE, LLC$294.2M
ELUSYS THERAPEUTICS INC$200.4M
CERUS CORPORATION$185.5M
JANSSEN VACCINES & PREVENTION B.V.$181.2M
Spending by State
| State | Funding | Awards |
|---|---|---|
| Colorado | $10.31B | 7 |
| Maryland | $2.08B | 140 |
| New York | $1.47B | 10 |
| New Jersey | $632.0M | 5 |
| California | $313.1M | 27 |
| Virginia | $226.4M | 21 |
| North Carolina | $164.5M | 23 |
| Massachusetts | $111.4M | 11 |
| Ohio | $96.9M | 28 |
| Wisconsin | $92.6M | 2 |
| Pennsylvania | $87.6M | 14 |
| Georgia | $67.7M | 9 |
| Iowa | $65.1M | 1 |
| Utah | $34.9M | 15 |
| Texas | $29.8M | 23 |
| Alabama | $29.7M | 23 |
| Washington | $29.6M | 2 |
| District of Columbia | $15.5M | 3 |
| New Hampshire | $8.9M | 1 |
| Connecticut | $8.1M | 1 |
| New Mexico | $7.4M | 4 |
| Illinois | $6.7M | 3 |
| Indiana | $6.5M | 2 |
| Louisiana | $5.9M | 2 |
| Oklahoma | $5.6M | 2 |
| Delaware | $2.0M | 1 |
| South Carolina | $1000K | 1 |
| Florida | $635K | 2 |
| Mississippi | $500K | 7 |
| Tennessee | $180K | 18 |
| Michigan | $100K | 1 |
| Vermont | $80K | 1 |
| Missouri | $10K | 1 |
Source: USAspending.gov · All Industries